高剂量与低剂量缩宫素方案用于引产增强的系统评价与荟萃分析
该系统评价与荟萃分析纳入10项随机及半随机对照试验共5508例妊娠,比较高剂量与低剂量缩宫素方案用于引产增强的效果。两组在5分钟Apgar评分<7和脐动脉pH<7.00风险上无差异,高剂量组绒毛膜羊膜炎风险显著降低(RR 0.70;95%CI 0.57-0.84;需治疗人数=25),但子宫过度刺激风险升高(RR 1.32;95%CI 1.21-1.43;P<.001)。
要点
- 高剂量与低剂量缩宫素方案在5分钟Apgar评分<7和脐动脉pH<7.00风险上无差异。
- 高剂量缩宫素方案与绒毛膜羊膜炎风险显著降低相关(RR 0.70;95%CI 0.57-0.84;需治疗人数=25)。
- 高剂量缩宫素方案与子宫过度刺激风险升高相关(RR 1.32;95%CI 1.21-1.43;P<.001)。
核心结论
- 用于引产增强时,高剂量缩宫素方案较底剂量方案降低绒毛膜羊膜炎风险,且不影响低Apgar评分、新生儿酸中毒或剖宫产的风险。
研究设计与样本
- 系统评价与荟萃分析,纳入10项随机及半随机对照试验共5508例妊娠,检索MEDLINE、Embase、Cochrane Library、CINAHL、Scopus、ClinicalTrials.gov自建库至2024年3月。
- 高剂量方案定义为起始缩宫素剂量≥4 mU/min、每15至40分钟增加3至7 mU/min;低剂量方案定义为起始剂量<4 mU/min、每15至40分钟增加1至2 mU/min。
- 纳入初产妇或多产妇接受引产增强者,比较持续缩宫素输注高剂量方案(干预组)与低剂量方案(对照组)。
- 采用随机效应头对头荟萃分析,报告汇总风险比及95%置信区间。
主要发现
- 5分钟Apgar评分<7风险无差异(RR 0.94;95%CI 0.60-1.46)。
- 脐动脉pH<7.00风险无差异(RR 0.77;95%CI 0.50-1.20)。
- 剖宫产风险无差异(RR 0.83;95%CI 0.67-1.02)。
- 高剂量组绒毛膜羊膜炎风险显著低于低剂量组(RR 0.70;95%CI 0.57-0.84;需治疗人数=25)。
- 高剂量组子宫过度刺激风险显著高于低剂量组(RR 1.32;95%CI 1.21-1.43;P<.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to assess whether high- vs low-dose oxytocin regimens for labor augmentation are associated with differential risk of low Apgar score, neonatal acidosis, and other adverse labor outcomes. DATA SOURCES: We searched electronic databases (MEDLINE, Embase, the Cochrane Library, CINAHL, Scopus, ClinicalTrials.gov) from inception up to March 2024 using combinations of the following key words: "oxytocin," "oxytocin regimen," "oxytocin protocol," "oxytocin dosage," "active management," "high dose protocol," "low dose protocol," and "augmentation of labor." STUDY ELIGIBILITY CRITERIA: We included quasi-randomized and randomized controlled trials comparing continuous oxytocin infusion with high-dose regimens (intervention group) vs low-dose regimens (control group) in nulliparous or multiparous patients undergoing labor augmentation. High-dose regimens were defined as a starting oxytocin dose of ≥4 mU/min, increasing in increments of 3 to 7 mU/min every 15 to 40 minutes. Low-dose regimens were defined as a starting oxytocin dose of <4 mU/min, increasing in increments of 1 to 2 mU/min every 15 to 40 minutes (PROSPERO CRD42024500197). METHODS: The coprimary outcomes were incidence of Apgar score <7 at 5 minutes and umbilical arterial pH <7.00. The secondary outcomes included cesarean delivery and chorioamnionitis. We performed random-effects head-to-head meta-analyses to compare high-dose with low-dose strategies, and reported summary risk ratios with 95% confidence intervals. RESULTS: Ten randomized and quasi-randomized controlled trials of 5508 pregnancies met the inclusion criteria and were included in this meta-analysis. There was no difference in risk for the coprimary outcomes of Apgar score <7 at 5 minutes (relative risk, 0.94; 95% confidence interval, 0.60-1.46) and umbilical arterial pH <7.00 (relative risk, 0.77; 95% confidence interval, 0.50-1.20). There was also no difference in risk for cesarean delivery (relative risk, 0.83; 95% confidence interval, 0.67-1.02). High-dose oxytocin regimens were associated with significantly lower risk of chorioamnionitis (relative risk, 0.70; 95% confidence interval, 0.57-0.84; number needed to treat=25) and higher risk of tachysystole (relative risk, 1.32; 95% confidence interval, 1.21-1.43; P<.001). CONCLUSION: When used for labor augmentation, high-dose oxytocin regimens decreased the risk of chorioamnionitis compared with low-dose regimens without affecting the risk of low Apgar scores, neonatal acidosis, or cesarean delivery. El resumen está disponible en Español al final del artículo.
引用
- Logue TC, Zullo F, van Biema F, et al. High- vs low-dose oxytocin regimens for labor augmentation: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2025. PMID: 39788427. doi:10.1016/j.ajogmf.2025.101604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。